Glenmark Pharmaceuticals is targeting a 10-11% increase in revenues and aims to reduce debt through free cash generation in the current financial year. The company also plans to expand its presence in therapeutic segments like oncology and dermatology while improving EBITDA margins. Glenmark reported consolidated revenue of Rs 12,990 crore in FY23, with an EBITDA of Rs 2,278 crore and net debt of Rs 2,905 crore.
